2026-08-27
TAME is prepared while launch funding is raised
The metformin trial design and site network are prepared; AFAR continues raising the money needed to begin the multi-site study.
See what this means for you →NEW RESULTS AND OPENINGS
Developments that may change your next move.
Each item is tied to a date and a specific project, result or access route.
2026-08-11
XPRIZE chooses 20 healthspan finalists
Twenty teams are moving towards coordinated human trials. Ten received $1 million milestone awards.
See what this means for you →2026-07-13
Vandria completes the first human test of VNA-318
The 92-person study supplied safety, dosing and target-engagement results for a medicine designed to improve mitochondrial cleanup.
See what this means for you →2026-07-10
NewLimit reports durable liver-cell resilience
The company reported animal results and manufacturing work needed before its planned first human study in 2027.
See what this means for you →2026-07-08
Elamipretide begins its required Phase 4 study
The first participant entered the study that must confirm the benefit behind the US accelerated approval for Barth syndrome.
See what this means for you →2026-06-15
Rubedo reports the first Phase 1b/2a skin results
The company reported an early four-week change in precancerous skin lesions while continuing to test RLS-1496 in people.
See what this means for you →2026-06-09
Cell reprogramming enters a human study
Life Biosciences dosed the first participant in the Phase 1 ER-100 optic-nerve study.
See what this means for you →2026-04-21
BioAge reports the first BGE-102 human data
The Phase 1 study supplied early safety and biological-response data before planned proof-of-concept studies in people with age-linked conditions.
See what this means for you →2026-03-04
TPN-101 receives ARPA-H support
Transposon is using the award to move its LINE-1 medicine towards larger studies in neurodegenerative disease.
See what this means for you →2026-02-24
ARPA-H starts seven healthspan programmes
The five-year PROSPR programme is investing up to $144 million in measurements, medicines and new trial designs.
See what this means for you →2026-02-24
FAST searches old trials for ageing signals
Columbia researchers are combining completed human trials to find biomarkers that respond to useful interventions.
See what this means for you →2026-01-26
External bioengineered liver completes Phase 1
Five people received miroliverELAP support; the company reported that the study met its main treatment-period safety goal.
See what this means for you →2026-01-13
LOY-002 completes another approval step
Loyal says two of three major FDA requirements are complete while the 1,300-dog STAY study continues.
See what this means for you →2025-11-03
The first UKidney is transplanted in EXPAND
United Therapeutics completed the first transplant in its formal Phase 1/2/3 xenokidney trial.
See what this means for you →2025-09-08
eGenesis can begin the EGEN-2784 trial
The FDA cleared a combined Phase 1/2/3 study of the company’s gene-edited pig kidney.
See what this means for you →2025-03-04
LyGenesis liver-cell study moves to the next group
After reviewing the first four participants, the independent safety board allowed the Phase 2a study to continue at a higher dose.
See what this means for you →